Latest United States News

OncoSil Medical enters FY27 with FDA approval for its cancer device, rising quarterly revenue and fresh institutional funding, but its U.S. opportunity still depends on reimbursement and a tightly controlled initial rollout. Cash rose to A$8.7 million after the capital raise, while operating cash use remained substantial.

xReality Group expanded its Operator XR customer base, recurring revenue and sales pipeline in the first quarter, while securing its first US Marine Corps order after quarter end. But the company remains focused on completing its FY26 audit and reinstating trading, with $1.4 million in quarter-end cash against $4.55 million of secured debt.

Astron has cleared a major financing hurdle for its Donald Project, with government-backed lenders conditionally approving up to A$180 million toward a proposed A$200 million Phase 1 debt facility. The project still needs commercial lender commitments, joint venture approval and a final investment decision targeted for Q4 2026.

Clever Culture Systems has started FY27 with three APAS Independence sales to Novo Nordisk and AstraZeneca, while targeting eight first-half sales and evaluations. The sales momentum comes with $1.6 million of unsecured loans due in December and a proposed extension still to be secured.

Clinuvel has submitted NEURACTHEL Instant for regulatory review in three initial European Union markets, opening a potential pathway for its second pharmaceutical product. The decentralised review is expected to take 300 days, excluding clock stops, but the product is not yet approved anywhere.

The Calmer Co. posted record Q1 FY27 revenue of A$2.44 million, powered by a sharp lift in US wholesale orders and continued Coles and Woolworths growth. But with A$953,000 in cash against quarterly operating outflows of A$755,000, the kava company remains dependent on further funding and sustained sales momentum.

ImpediMed lifted quarterly revenue and recurring revenue, but weaker-than-expected BCRL sales and a near-total sales team rebuild have put its path to cash-flow break-even under pressure. The company ended September with $11.6 million in cash and 4.7 quarters of funding at the quarter’s operating burn.

Ardea Resources and its Japanese consortium partners will add an approximately nine-month Pre-FEED phase before finalising the Goongarrie Hub feasibility study and moving to FEED. The decision resets the previously advised DFS timing and funding arrangements while opening new work on cost reduction, scandium and gold.

Blue Star Helium has recorded its first commercial helium sales from the Pinon Canyon plant in Colorado, delivering five tube trailers during the September quarter. The milestone comes with an extended offtake agreement through March 2027, but production growth still depends on permits, well development and funding.

Yowie Group has entered FY27 with US$71,000 in cash, a 35% drop in US gross sales and a fully drawn A$4 million working capital facility. The confectionery maker is pursuing an approximately A$6 million two-tranche capital raising while its ASX quotation remains suspended.

Impact Minerals is recasting itself as a high-purity alumina developer, with Lake Hope advancing towards a definitive feasibility study and Alluminous reaching pilot-plant milestones. But the annual report also flags a material uncertainty over funding, while a board refresh and managing director departure add to the company’s transition.

RMA Global delivered positive underlying EBITDA of A$0.12 million in the first quarter of FY27, despite weaker customer receipts and revenue. More than A$1.50 million in annualised costs has been removed, but cash of A$1.66 million leaves limited room for execution missteps.